// App-Quantinova.ai

701P : PHASE IB TRIAL TO EVALUATE CAPECITABINE (C), ERLOTINIB (E), AND BEVACIZUMAB (B) IN PATIENTS (PTS) WITH UNRESECTABLE AND/OR METASTATIC PANCREATIC CANCER (UMPC) PRELIMINARY RESULTS OF THE REBECA TRIAL INCLUDING PHARMACOKINETICS (PK) AND CIRCULATING TUMOR CELLS (CTCS)

Researchers

Presenter

  • C. Dittrich

Principal Investigators

  • P. Buchner

  • A. Sahmanovic

  • R. Konigsberg

  • M. Lichtneckert

  • G. Nirnberger

  • M. Czejka

  • K. Geissler

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Translational Resear

  • Bioconsult Ltd

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Capecitabine

  • Bevacizumab

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved